Pular para o conteúdo
Merck
Todas as fotos(2)

Documentos

M0696

Sigma-Aldrich

Anti-MNK2 (N-terminal) antibody produced in rabbit

enhanced validation

~1.0 mg/mL, affinity isolated antibody, buffered aqueous solution

Sinônimo(s):

Anti-GPRK7, Anti-MAP kinase interacting serine/threonine kinase 2, Anti-MKNK2

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(2)

About This Item

Código UNSPSC:
12352203
NACRES:
NA.44

fonte biológica

rabbit

conjugado

unconjugated

forma do anticorpo

affinity isolated antibody

tipo de produto de anticorpo

primary antibodies

clone

polyclonal

forma

buffered aqueous solution

peso molecular

antigen ~50 kDa

reatividade de espécies

rat (predicted), human, mouse (predicted)

validação aprimorada

recombinant expression
Learn more about Antibody Enhanced Validation

concentração

~1.0 mg/mL

técnica(s)

immunocytochemistry: 2-5 μg/mL using paraformadehyde fixed HEK-293T cells transfected with human MNK2
immunoprecipitation (IP): 2-4 μg using lysates of HEK-293T cells transfected with human MNK2
indirect immunofluorescence: suitable
western blot: 1-2 μg/mL using lysates of HEK-293T cells transfected with human MNK2

nº de adesão UniProt

Q9HBH9

Condições de expedição

dry ice

temperatura de armazenamento

−20°C

modificação pós-traducional do alvo

unmodified

Informações sobre genes

human ... MKNK2(2872)
mouse ... Mknk2(17347)
rat ... Mknk2(299618)

Descrição geral

MNK2 is a serine threonine kinase that phosphorylates endogenous eIF4E and thereby regulates protein translation and cell growth. This kinase inhibits apoptotic responses induced by arsenic trioxide. MNK2 has two distinct splice forms, namely; MNK2a and MNK2b. The localization and function of MNK2 splice variants are directed by their N and C termini . Anti-MNK2 (N-terminal) antibody is specific for human MNK2. The antibody is also expected to react with mouse and rat MNK2. In immunoblotting, staining of the MNK2 band is specifically inhibited by the immunizing peptide.

Imunogênio

synthetic peptide corresponding to amino acids 51-64 of human MNK2 (corresponding to isoforms 1 and 2), conjugated to KLH via a C-terminal added cysteine residue. The corresponding sequence is conserved in human, rat, and mouse.

Aplicação

Anti-MNK2 (N-terminal) antibody is suitable for use in immunocytochemistry (2-5 μg/mL using paraformaldehyde fixed, MNK2-transfected, HEK-293T cells) and indirect immunofluorescence. The antibody may also be used for immunoprecipitation (2-4 μg) and western blot (1-2 μg/mL) using lysates of HEK-293T cells transfected with human MNK2.

forma física

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Exoneração de responsabilidade

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Ferramenta de seleção de produtos.

Código de classe de armazenamento

10 - Combustible liquids

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)

Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Y Shi et al.
Oncogene, 32(2), 190-197 (2012-03-01)
When mTOR inhibitor rapalogs prevent cap-dependent translation of cell-cycle proteins like c-myc, continuing tumor cell growth depends on cap-independent translation, which is mediated by internal ribosome entry sites (IRESes) located in the 5'-UTR (untranslated region) of transcripts. To investigate if
Senthilmurugan Ramalingam et al.
Cancers, 11(3) (2019-03-06)
Currently, there are no effective therapies for patients with triple-negative breast cancer (TNBC), an aggressive and highly metastatic disease. Activation of eukaryotic initiation factor 4E (eIF4E) by mitogen-activated protein kinase (MAPK)-interacting kinases 1 and 2 (Mnk1/2) play a critical role
Gert C Scheper et al.
Molecular and cellular biology, 23(16), 5692-5705 (2003-08-05)
The cap-binding eukaryotic initiation factor eIF4E is phosphorylated by the mitogen-activated protein (MAP) kinase-interacting kinases (Mnk's). Three forms of the Mnk's exist in human cells: Mnk1, Mnk2a, and Mnk2b. These last two are derived from the same gene by alternative
G C Scheper et al.
Molecular and cellular biology, 21(3), 743-754 (2001-01-12)
The cap-binding translation initiation factor eukaryotic initiation factor 4E (eIF4E) is phosphorylated in vivo at Ser209 in response to a variety of stimuli. In this paper, we show that the mitogen-activated protein kinase (MAPK) signal-integrating kinase Mnk2 phosphorylates eIF4E at
U Knauf et al.
Molecular and cellular biology, 21(16), 5500-5511 (2001-07-21)
Eukaryotic initiation factor 4E (eIF4E) is a key component of the translational machinery and an important modulator of cell growth and proliferation. The activity of eIF4E is thought to be regulated by interaction with inhibitory binding proteins (4E-BPs) and phosphorylation
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica